Widely used:Recently Viewed
Clear AllToday’s Range
52 Week Range
Liquidity
Market cap
$78,830 Mln
Revenue (TTM)
$31,529 Mln
Net Profit (TTM)
$0 Mln
ROE
0.3 %
ROCE
-- %
P/E Ratio
18.9
P/B Ratio
4.1
Industry P/E
28.02
EV/EBITDA
9.4
Div. Yield
4.1 %
Debt to Equity
0
Book Value
$--
EPS
$1.5
Face value
--
Shares outstanding
2,024,690,048
CFO
£67,745.00 Mln
EBITDA
£82,554.00 Mln
Net Profit
£41,873.00 Mln
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
GlaxoSmithKline - ADR
| 13.2 | -1.7 | -2.5 | -5.4 | 3.8 | 2.7 | 0.8 |
|
BSE Sensex
| 4.7 | 1.2 | 6.5 | 6.1 | 16.5 | 18.6 | 11.4 |
|
Company
|
2024
|
2023
|
2022
|
2021
|
2020
|
2019
|
2018
|
|---|---|---|---|---|---|---|---|
|
GlaxoSmithKline - ADR
| -8.7 | 5.5 | -20.3 | 19.8 | -21.7 | 23.0 | 7.7 |
|
BSE Sensex
| 8.1 | 18.7 | 4.4 | 22.0 | 15.8 | 14.4 | 5.9 |
|
BSE Sensex
| 8.1 | 18.7 | 4.4 | 22.0 | 15.8 | 14.4 | 5.9 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, specialty medicines, and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It... operates through Commercial Operations and Total R&D segments. The company offers specialty medicines that include oncology, respiratory/immunology, inflammation, and inhaled medicines for HIV, respiratory eosinophildriven diseases, lupus and lupus nephritis, ovarian cancer, and endometrial cancer. It also provides vaccines for Shingles, Meningitis, RSV, Seasonal Influenza, Hepatitis, Diphtheria, Tetanus, Acellular Pertussis, Rotavirus, Pertussis, Polio, Haemophilus, Invasive Diseases, Pneumonia, Acute Otitis Media, Measles, Mumps, Rubella and Chickenpox, and Human Papilloma Virus. Additionally, the company offers general medicines for asthma, COPD, bacterial infection, benign prostatic hyperplasia, allergic rhinitis, and inflammatory skin conditions. It has a collaboration agreement with CureVac to develop mRNA vaccines for infectious diseases. The company was formerly known as GlaxoSmithKline plc and changed its name to GSK plc in May 2022. GSK plc was founded in 1715 and is headquartered in London, United Kingdom. Read more
CEO & Director
Ms. Emma Natasha Walmsley
CEO & Director
Ms. Emma Natasha Walmsley
Headquarters
London
Website
Our rating system has guided millions of investors in the past 20 years.
The total asset value of GlaxoSmithKline PLC - ADR stood at $ 81,536 Mln as on 31-Mar-25
The share price of GlaxoSmithKline PLC - ADR is $38.28 (NYSE) as of 23-Jun-2025 13:49 EDT. GlaxoSmithKline PLC - ADR has given a return of 3.84% in the last 3 years.
GlaxoSmithKline PLC - ADR has a market capitalisation of $ 78,830 Mln as on 20-Jun-2025. As per Value Research classification, it is a company.
The P/B ratio of GlaxoSmithKline PLC - ADR is 4.06 times as on 20-Jun-2025, a 14% discount to its peers’ median range of 4.74 times.
The P/E ratio of GlaxoSmithKline PLC - ADR is 18.94 times as on 20-Jun-2025, a 32% discount to its peers’ median range of 28.02 times.
Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
Step 4. Search for the GlaxoSmithKline PLC - ADR and enter the required number of quantities and click on buy to purchase the shares of GlaxoSmithKline PLC - ADR.
GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, specialty medicines, and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through Commercial Operations and Total R&D segments. The company offers specialty medicines that include oncology, respiratory/immunology, inflammation, and inhaled medicines for HIV, respiratory eosinophildriven diseases, lupus and lupus nephritis, ovarian cancer, and endometrial cancer. It also provides vaccines for Shingles, Meningitis, RSV, Seasonal Influenza, Hepatitis, Diphtheria, Tetanus, Acellular Pertussis, Rotavirus, Pertussis, Polio, Haemophilus, Invasive Diseases, Pneumonia, Acute Otitis Media, Measles, Mumps, Rubella and Chickenpox, and Human Papilloma Virus. Additionally, the company offers general medicines for asthma, COPD, bacterial infection, benign prostatic hyperplasia, allergic rhinitis, and inflammatory skin conditions. It has a collaboration agreement with CureVac to develop mRNA vaccines for infectious diseases. The company was formerly known as GlaxoSmithKline plc and changed its name to GSK plc in May 2022. GSK plc was founded in 1715 and is headquartered in London, United Kingdom.
The CEO & director of Ms. Emma Natasha Walmsley. is GlaxoSmithKline PLC - ADR, and CFO & Sr. VP is Ms. Emma Natasha Walmsley.
There is no promoter pledging in GlaxoSmithKline PLC - ADR.
Some of the close peers are:
| Company | Market Cap($ Mln) |
|---|
| GlaxoSmithKline PLC - ADR | Ratios |
|---|---|
|
Return on equity(%)
|
18.92
|
|
Operating margin(%)
|
17.17
|
|
Net Margin(%)
|
10
|
|
Dividend yield(%)
|
--
|
No, TTM profit after tax of GlaxoSmithKline PLC - ADR was $0 Mln.
$0.21
(
